Drug Trial Radar · NCT05211895
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
791
Actual
Start
Feb 18, 2022
Primary completion
Aug 10, 2026
Study completion Sep 8, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Arcus Biosciences, Inc.
- First posted
- Jan 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Conditions
- Non-Small Cell Lung Cancer
Interventions
DurvalumabDrug
Durvalumab IV (Intravenous infusion)
DomvanalimabDrug
Domvanalimab IV (Intravenous infusion)
PlaceboOther
Placebo IV (Intravenous infusion)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to 5 years after randomization
Locations
226 sites in 28 countries. Site status is shown where the registry gives one.
Research Site
Chandler, Arizona
Research Site
Phoenix, Arizona
Research Site
Fountain Valley, California
Research Site
Santa Rosa, California
Research Site
Washington D.C., District of Columbia
Research Site
Jacksonville, Florida
Research Site
Orlando, Florida
Research Site
Saint Augustine, Florida
Research Site
Macon, Georgia
Research Site
Elmhurst, Illinois
Research Site
Louisville, Kentucky
Research Site
Baltimore, Maryland
Research Site
Silver Spring, Maryland
Research Site
Ann Arbor, Michigan
Research Site
Detroit, Michigan
Research Site
Minneapolis, Minnesota
Research Site
Rochester, Minnesota
Research Site
Reno, Nevada
Research Site
East Brunswick, New Jersey
Research Site
Columbus, Ohio
Research Site
Maumee, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Pittsburgh, Pennsylvania
Research Site
Charleston, South Carolina
Research Site
Chattanooga, Tennessee
Research Site
Nashville, Tennessee
Research Site
Nashville, Tennessee
Research Site
Fort Sam Houston, Texas
Research Site
Fairfax, Virginia
Research Site
Fort Belvoir, Virginia
Research Site
Spokane Valley, Washington
Research Site
Appleton, Wisconsin
Research Site
Brussels, Belgium
Research Site
Edegem, Belgium
Research Site
Haine-Saint-Paul, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Sint-Niklaas, Belgium
Research Site
Barretos, Brazil
Research Site
Londrina, Brazil
Showing 40 of 226 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.